Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
about
Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic ratsFundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's diseaseTherapeutic and diagnostic challenges for frontotemporal dementiaImmunotherapeutic approaches for Alzheimer's diseaseYokukansan inhibits neuronal death during ER stress by regulating the unfolded protein responsePassive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseDopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicityAffinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.Targeting Abeta and tau in Alzheimer's disease, an early interim reportNovel immunological approaches for the treatment of Alzheimer's disease.Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificityImmunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse modelThe many faces of tauRecent Alzheimer's disease research highlights.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.Neurodegenerative disorders and nanoformulated drug development.Mechanism-based treatments for Alzheimer's disease.Therapeutic strategies for tau mediated neurodegeneration.Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Inflammation in Alzheimer's disease: relevance to pathogenesis and therapyMurine models of Alzheimer's disease and their use in developing immunotherapies.The role of tau in Alzheimer's disease and related disorders.Therapeutic applications of antibodies in non-infectious neurodegenerative diseasesProtein aggregate spreading in neurodegenerative diseases: problems and perspectivesTau as a therapeutic target for Alzheimer's diseaseImmunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Open questions for Alzheimer's disease immunotherapy.Active immunotherapy options for Alzheimer's disease.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Tau Immunotherapy.Developing therapeutic vaccines against Alzheimer's disease.Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model.Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies
P2860
Q26747585-34B69A37-C937-42CD-8107-01B1721C3D6BQ26748713-0A46C15B-3B59-4F4A-A5A9-E2430037A722Q26998919-0EFAC5FC-29AD-4F6C-8085-A58F5D5AF84AQ28081278-A6CFC3C0-1A68-417D-A533-1DA477843699Q28475740-77367B91-A380-4D0E-B236-B63EFA57D12BQ28740551-72893190-AF58-4945-8049-029F1C319A2AQ30535414-3E055D89-E806-45F0-85D9-EA66DEBA2442Q30805841-D394C8DB-3E4D-4951-A6D1-1B9BD1C6CC08Q33742312-2762FF90-C6A0-4964-AA8C-2B7C430911B2Q33829008-DA593F42-2677-49C8-9ACD-DB60AC207501Q34562675-3DB450C4-C40B-42A0-9318-30447FEE9CD7Q34629320-41C08529-CF5B-42E4-A9C8-6F65178E355AQ34701388-9E727176-07DD-4C58-B53F-5737D53CB08CQ35104249-0958DE30-7F64-475F-8673-BB74144CDF93Q35870359-46AAC62F-317C-4B81-9219-50C453DB6320Q36424806-6EBC9951-FDBE-4454-BD64-E351F752DED5Q36558485-B33A6FFB-826A-4662-AAF7-296C67CBC203Q37057272-82B84993-18DB-447C-86A4-A6589D9044D2Q37117527-24F85CAB-6512-4B66-B3DF-FE2421986CF6Q37538771-B53927F3-CBC5-4DBA-BC2C-E97A645AB5F4Q37544756-799F3697-B358-44A5-919A-3F9D849B7D74Q37550818-1AF604AF-3F3F-4EDB-B2ED-45E4B3C88967Q37623855-E3E62B18-5332-4BCE-8BC0-E5139FFBA93EQ37655247-652C53F2-E128-4985-B6B7-3ADAA600F82CQ37681432-D0514B78-B8B4-430D-99A3-9F7900EFADF9Q37685285-25F50270-F132-4A30-92CF-34545A6BAAA3Q37752915-27889994-369E-40FE-A01E-9DF656D640F2Q37765632-BAF09253-ABEB-480B-A6F9-9396AD99AB00Q37862785-34D80D26-08F5-45E3-8B8E-A65FB6DC2E55Q37882078-B126A054-9071-4363-9904-5E410852D977Q37890451-791C9E2B-090C-4EE1-8FFA-B102358618A5Q38079317-8CA6AACE-9FA2-4844-A064-7BEA1A3CC934Q38176097-C5C104CA-B692-4685-8BA6-92CB77916934Q38183140-6A3FBB46-18A2-4470-AF9E-1584692761F4Q38283308-48856F59-8E5A-4B8A-AF17-4488EEAA5A28Q38628672-5FCC51E5-AC8C-4AF3-BB67-359B1E6564BAQ38636151-5F1D6FEE-353F-45C8-AC5D-4523ECFD42A0Q38773662-0B64189C-1840-4EAB-A6CA-1DF6A539CB52Q40141995-A1E24840-E8EC-467C-81F4-3F80B0A61F5CQ42371467-0F7B8D3D-A4F5-47D7-8C7E-5F989C9A0F7A
P2860
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy targeting pathol ...... sease and related tauopathies.
@en
Immunotherapy targeting pathol ...... sease and related tauopathies.
@nl
type
label
Immunotherapy targeting pathol ...... sease and related tauopathies.
@en
Immunotherapy targeting pathol ...... sease and related tauopathies.
@nl
prefLabel
Immunotherapy targeting pathol ...... sease and related tauopathies.
@en
Immunotherapy targeting pathol ...... sease and related tauopathies.
@nl
P2860
P356
P1476
Immunotherapy targeting pathol ...... isease and related tauopathies
@en
P2093
Einar M Sigurdsson
P2860
P304
P356
10.3233/JAD-2008-15202
P577
2008-10-01T00:00:00Z